Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-T0920 in DLBCL and Other Aggressive B-Cell Malignancies
NCT07887646Phase 1Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2026
- Primary completion
- Oct 2029
01
Overview
Phase 1, open-label trial of BG-T0920 in diffuse large B-cell lymphoma (DLBCL) and B-cell malignancy (2 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-limiting Toxicities at 1 month and Treatment-emergent Adverse Events, Treatment-related Adverse Events, and Serious Adverse Events at 13 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BG-T0920
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B-cell malignancy
Beyond the preview
Go deeper on NCT07887646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887646.